Doctors and drug companies aim to reduce blood fat levels through medications like Lipitor, but the benefits in lives saved by these drugs fall short of expectations. Well-informed patients will resolve elevated cholesterol and triglyceride values by dealing with the cause: a diet high in animal products and low in plant foods. Beginning with an average cholesterol level of 220 mg/dl (5.79 IU), you can expect a 30 mg (1.1 IU) reduction in your cholesterol level in 2 weeks. If your cholesterol level is higher than that, then you can probably expect and even bigger improvement. Triglyceride reductions can also be dramatic but simple sugars, including fruit and juice, must be limited or eliminated for the best results.
Related Newsletter Articles
(articles open in a new window)
- May 2013: Who Should Take Cholesterol-lowering Statins? Everyone or No One?
- February 2005: The McDougall Program Cures People; The Risk Factor Improvements Are Incidental
- June 2003: Cleaning Out Your Arteries
- May 2007: Who Should Take Statins?
- September 2010: Statins Fail to Save Lives
- July 2011: Niacin Combined with a Statin Is Dangerous
- November 2008: Crestor (Jupiter) Expands the Indications for Statins—and the Public Suffers
- Red Yeast Rice Is an Alternative to Statins for Cholesterol-Lowering
- February 2008: Intensive Therapy Means You Will Die Sooner with Good Looking Numbers
- September 2002: Cholesterol – When and How to Treat
- September 2009: Cholesterol-lowering Statins Weaken Muscles and Cause Falls
- February 2003: Niacin – A Time Honored Treatment for Cholesterol and Triglycerides
- March 2005: Eggs Are for Easter
- January 2003: Taming Elevated Triglycerides, Insulin Resistance, and Syndrome X
- April 2004: HDL “Good” Cholesterol is Not Worth Your Attention
- December 2003: Plant-based Diets Reduce C-Reactive Protein and Heart Disease
- February 2007: Disease Mongering: New Women’s Guidelines for Heart Disease
- June 2008: A Posthumous Interview by Tim Russert, Former Host of Meet the Press with John McDougall, MD
Related Success Stories
Related Independent Research
Blackburn H. 20th-Century “Medical Marco Polos” in the Origins of Preventive Cardiology and Cardiovascular Disease Epidemiology. Amer J Card. 2012 March 1;109(5): 756-767.
http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS0002914911032127.pdf
Capewell S and Ford ES. Why have total cholesterol levels declined in most developed countries? BMC Public Health. 2011; 11:641. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199603/pdf/1471-2458-11-641.pdf
Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ. 1997; 314:112
http://www.bmj.com/content/314/7074/112.abstract
de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010 Jun 28; 170(12):1032-6. http://archinte.jamanetwork.com/article.aspx?articleid=416101
Kullo IJ. Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med. 1998 Dec 15; 129(12):1050-60. http://annals.org/article.aspx?articleid=712395
Page IH. Prediction of coronary heart disease based on clinical suspicion, age, total cholesterol, and triglyceride. Circulation. 1970 Oct; 42(4):625-45. http://circ.ahajournals.org/content/42/4/625.full.pdf
Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010 Jun 28; 170(12):1024-31. http://www.ncbi.nlm.nih.gov/pubmed/20585067
Sdringola S. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol. 2003 Jan 15; 41(2):263-72. http://www.sciencedirect.com/science/article/pii/S0735109702026931
Zhou J. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scand J Clin Lab Invest Suppl. 1999; 230:3-11.
http://informahealthcare.com/doi/abs/10.1080/00365519909168321
